Omar Shamsi, MD
Obesity Medicine · Elmhurst, ILNPI 1053599233
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,150 of the $38,844 with a category attached, or 62.2%. Lilly USA, LLC accounts for 71.0% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $29,850, more than ten times the $2,951 reported in 2019.
Across 450 payments — averaging $86.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$28K
- Novo Nordisk$7K
- Endo Pharmaceuticals Inc.$614
- Aimmune Therapeutics, Inc.$546
- AbbVie$520
- Takeda Pharmaceuticals U.S.A., Inc.$340
- plus $2K from 17 others
What the payments were for
- Consulting fees$4,09411%
- Speaking & faculty fees$24,15062%
- Travel & lodging$2,3646%
- Food & beverage$8,21421%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 74 | $27,576 |
| Novo Nordisk | 126 | $7,014 |
| Endo Pharmaceuticals Inc. | 46 | $614 |
| Aimmune Therapeutics, Inc. | 46 | $546 |
| AbbVie | 14 | $520 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $340 |
| Bausch Health US, LLC | 17 | $308 |
| Currax Pharmaceuticals LLC | 16 | $245 |
| Xeris Pharmaceuticals, Inc. | 5 | $196 |
| Jazz Pharmaceuticals Inc. | 5 | $183 |
| Shire North American Group Inc | 13 | $166 |
| Kvk-tech, Inc. | 25 | $140 |
| Nestle Healthcare Nutrition Inc. | 11 | $137 |
| Rhythm Pharmaceuticals, Inc. | 2 | $129 |
| Amarin Pharma, Inc. | 1 | $122 |
| Phathom Pharmaceuticals, Inc. | 3 | $111 |
| Corcept Therapeutics | 4 | $103 |
| Upsher-smith Laboratories LLC | 5 | $96 |
| Eisai Inc. | 4 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $77 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Abbott | 3 | $60 |
| Nalpropion Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 189 | $208,860 |
| OzempicSemaglutide | 75 | $90,423 |
| MounjaroTirzepatide | 58 | $77,319 |
| WegovySemaglutide | 44 | $59,585 |
| RybelsusSemaglutide | 20 | $29,948 |
| VyvanseLisdexamfetamine Dimesylate | 37 | $14,357 |
| Lisdexamfetamine Dimesylate | 39 | $7,101 |
| Topiramate | 298 | $3,168 |
| Escitalopram Oxalate | 44 | $808 |
| Bupropion XlBupropion Hcl | 18 | $544 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $421 |
| Metformin Hcl ErMetformin Hcl | 62 | $232 |
| Hydrochlorothiazide | 33 | $196 |
| Sertraline Hcl | 31 | $171 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 22 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $27,576 | $286,179247 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $7,014 | $179,956139 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $340 | $14,35737 claims |
| Upsher-smith Laboratories LLCTopiramate | $96 | $3,168298 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Elmhurst
- Diala AlatassiElmhurst$815
- Jeffrey PuaWestmont$25K
- Diana PlataArlington Heights$19K
- Esmilkrys RamirezChicago$15K
- Mona LalaChicago$822
- Esther SchulzMount Vernon$485
- Catherine JohnsonClarendon Hills$324
- Darshan PatelDeer Park$266
- Lyndsay HoffmanArlington Heights$219
- Manali PatelBloomingdale$211
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.